Description
BSE notifies trading members that Aptus Pharma Limited has fixed a record date of May 12, 2026 for a bonus issue of 3 equity shares for every 2 equity shares held, with market lot revised from 2000 to 5000.
Summary
BSE has notified trading members that Aptus Pharma Limited (Scrip Code: 544529) has fixed May 12, 2026 as the record date for a bonus issue of equity shares. Shareholders will receive 3 bonus equity shares of Rs. 10/- each for every 2 equity shares of Rs. 10/- each held. Trading in the scrip will be on an ex-bonus basis from May 12, 2026.
Key Points
- Bonus ratio: 3 new equity shares for every 2 existing equity shares held
- Face value of bonus shares: Rs. 10/- each
- Record date: May 12, 2026
- Ex-bonus effective date: May 12, 2026 (Settlement No. DR-628/2026-2027)
- Total bonus shares to be allotted: 10,290,000 equity shares as on May 13, 2026
- Market lot revised from 2000 to 5000 shares, effective May 12, 2026
Regulatory Changes
The market lot for Aptus Pharma Limited (Scrip Code: 544529) is being changed pursuant to the bonus issue:
| Scrip Code | Scrip Name | Current Market Lot | Revised Market Lot |
|---|---|---|---|
| 544529 | APTUS PHARMA LIMITED | 2000 | 5000 |
Compliance Requirements
- Trading members must note the ex-bonus effective date of May 12, 2026 and ensure all transactions from that date reflect the adjusted price.
- Trading members must update order/trade systems to reflect the revised market lot of 5000 shares effective May 12, 2026.
- Members should refer to the attached company undertaking letter dated May 08, 2026 for additional details.
Important Dates
- May 8, 2026: BSE notice issued; company undertaking letter dated
- May 12, 2026: Record date for bonus issue; ex-bonus trading begins; revised market lot takes effect (Settlement No. DR-628/2026-2027)
- May 13, 2026: Allotment date for 10,290,000 bonus equity shares
Impact Assessment
Existing shareholders of Aptus Pharma Limited will see a 150% increase in their share count (3 new shares per 2 held), with a proportional adjustment in share price on the ex-bonus date. The market lot increase from 2000 to 5000 reflects the expanded share base post-bonus. This is a significant corporate action for retail and institutional investors holding the scrip, requiring attention to revised lot sizes for trading purposes.
Impact Justification
Directly affects existing shareholders of Aptus Pharma Limited with a 3:2 bonus issue ratio, ex-bonus trading adjustment, and market lot revision — all effective May 12, 2026.